2026 · Archives of gynecology and obstetrics · open access
Comparison of three different hpv self-sampling tools - a subanalysis of the prospective, randomized hannover self-collection study
Hempel et al.
The finding, in our words
This randomised sub-study found return rates of 10.4% for Colli-Pee, 10.1% for FLOQSwabs and 7.4% for Evalyn-Brush. All devices yielded sufficient DNA with low invalid rates, but the authors noted the study was limited by low overall participation.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
In 498 women living with HIV, self-collected first-void urine and vaginal samples showed 78% high-risk HPV prevalence and good genotype concordance, kappa 0.64-0.78. Participants preferred the Colli-Pee device over the Evalyn Brush, supporting decentralised, patient-centric screening feasibility.
Urine self-sampling for HPV showed non-inferior specificity to cervical samples, 85.19%, and found 96% of high-grade lesions. While acceptable, a survey of 1382 participants found 41.6% preferred conventional screening, showing the importance of offering choice in a decentralised, patient-centric programme.
First-void urine collected with the Colli-pee device detected high-grade cervical precancer with 90.3% sensitivity, substantially better than the 73.4% sensitivity of standard-pot urine, and was acceptable to colposcopy attendees. The device achieved 92% relative sensitivity compared with clinician-collected cervical samples, showing promise for decentralised HPV screening.
Among 515 women, 93% believed HPV self-sampling could improve screening uptake and 95% found instructions clear and felt confident, yet 41% still preferred clinician collection and 9-19% found it unpleasant. This shows urine-based screening with Colli-Pee is well accepted but not universally preferred, a crucial insight for patient-centric decentralised programmes.
Two dry vaginal self-sampling devices and a first-void urine collector detected over 90% of high-grade cervical lesions (CIN 3+) and all invasive cancers, with sensitivity comparable to clinician-taken smears. Participants found the devices easy to use and self-sampling was well accepted, which could improve uptake of cervical screening.